Cargando…
Identifying Early Neuropsychological Indicators of Cognitive Involvement in Multiple Sclerosis
Multiple sclerosis (MS) is a debilitating disease of the central nervous system that is most commonly seen in early to middle adulthood, although it can be diagnosed during childhood or later in life. While cognitive impairment can become more prevalent and severe as the disease progresses, signs of...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872925/ https://www.ncbi.nlm.nih.gov/pubmed/33574669 http://dx.doi.org/10.2147/NDT.S256689 |
_version_ | 1783649283852992512 |
---|---|
author | Gromisch, Elizabeth S Dhari, Zaenab |
author_facet | Gromisch, Elizabeth S Dhari, Zaenab |
author_sort | Gromisch, Elizabeth S |
collection | PubMed |
description | Multiple sclerosis (MS) is a debilitating disease of the central nervous system that is most commonly seen in early to middle adulthood, although it can be diagnosed during childhood or later in life. While cognitive impairment can become more prevalent and severe as the disease progresses, signs of cognitive involvement can be apparent in the early stages of the disease. In this review, we discuss the prevalence and types of cognitive impairment seen in early MS, including the specific measures used to identify them, as well as the challenges in characterizing their frequency and progression. In addition to examining the progression of early cognitive involvement over time, we explore the clinical factors associated with early cognitive involvement, including demographics, level of physical disability, disease modifying therapy use, vocational status, and psychological and physical symptoms. Given the prevalence and functional impact these impairments can have for persons with MS, considerations for clinicians are provided, such as the role of early cognitive screenings and the importance of comprehensive neuropsychological assessments. |
format | Online Article Text |
id | pubmed-7872925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78729252021-02-10 Identifying Early Neuropsychological Indicators of Cognitive Involvement in Multiple Sclerosis Gromisch, Elizabeth S Dhari, Zaenab Neuropsychiatr Dis Treat Review Multiple sclerosis (MS) is a debilitating disease of the central nervous system that is most commonly seen in early to middle adulthood, although it can be diagnosed during childhood or later in life. While cognitive impairment can become more prevalent and severe as the disease progresses, signs of cognitive involvement can be apparent in the early stages of the disease. In this review, we discuss the prevalence and types of cognitive impairment seen in early MS, including the specific measures used to identify them, as well as the challenges in characterizing their frequency and progression. In addition to examining the progression of early cognitive involvement over time, we explore the clinical factors associated with early cognitive involvement, including demographics, level of physical disability, disease modifying therapy use, vocational status, and psychological and physical symptoms. Given the prevalence and functional impact these impairments can have for persons with MS, considerations for clinicians are provided, such as the role of early cognitive screenings and the importance of comprehensive neuropsychological assessments. Dove 2021-02-05 /pmc/articles/PMC7872925/ /pubmed/33574669 http://dx.doi.org/10.2147/NDT.S256689 Text en © 2021 Gromisch and Dhari. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Gromisch, Elizabeth S Dhari, Zaenab Identifying Early Neuropsychological Indicators of Cognitive Involvement in Multiple Sclerosis |
title | Identifying Early Neuropsychological Indicators of Cognitive Involvement in Multiple Sclerosis |
title_full | Identifying Early Neuropsychological Indicators of Cognitive Involvement in Multiple Sclerosis |
title_fullStr | Identifying Early Neuropsychological Indicators of Cognitive Involvement in Multiple Sclerosis |
title_full_unstemmed | Identifying Early Neuropsychological Indicators of Cognitive Involvement in Multiple Sclerosis |
title_short | Identifying Early Neuropsychological Indicators of Cognitive Involvement in Multiple Sclerosis |
title_sort | identifying early neuropsychological indicators of cognitive involvement in multiple sclerosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872925/ https://www.ncbi.nlm.nih.gov/pubmed/33574669 http://dx.doi.org/10.2147/NDT.S256689 |
work_keys_str_mv | AT gromischelizabeths identifyingearlyneuropsychologicalindicatorsofcognitiveinvolvementinmultiplesclerosis AT dharizaenab identifyingearlyneuropsychologicalindicatorsofcognitiveinvolvementinmultiplesclerosis |